Cargando…

Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort

RATIONALE: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 is based on an ABCD assessment tool of symptoms and exacerbation history and grade 1–4 of airflow limitation severity, facilitating classification either into 4 groups (ABCD) or 16 groups (1A-4D). We aimed to compare t...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Lan Ai Kieu, Johannessen, Ane, Hardie, Jon Andrew, Johansen, Odd Erik, Gulsvik, Amund, Vikse, Bjørn Egil, Bakke, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662162/
https://www.ncbi.nlm.nih.gov/pubmed/31413559
http://dx.doi.org/10.2147/COPD.S194019
_version_ 1783439605370978304
author Le, Lan Ai Kieu
Johannessen, Ane
Hardie, Jon Andrew
Johansen, Odd Erik
Gulsvik, Amund
Vikse, Bjørn Egil
Bakke, Per
author_facet Le, Lan Ai Kieu
Johannessen, Ane
Hardie, Jon Andrew
Johansen, Odd Erik
Gulsvik, Amund
Vikse, Bjørn Egil
Bakke, Per
author_sort Le, Lan Ai Kieu
collection PubMed
description RATIONALE: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 is based on an ABCD assessment tool of symptoms and exacerbation history and grade 1–4 of airflow limitation severity, facilitating classification either into 4 groups (ABCD) or 16 groups (1A-4D). We aimed to compare the GOLD 2011, GOLD 2017 ABCD, and GOLD 2017 1A-4D classifications in terms of their distribution and prediction of mortality and hospitalizations. METHODS: In the GenKOLS study, 912 COPD patients with FEV1 less than 80% of the predicted answered questionnaires and performed lung function testing in 2003–2005. The patients were recruited from a hospital patient registry (n=662) and from the general population (n=250), followed up until 2011 with respect to all-cause and respiratory mortality, and all-cause and respiratory hospitalizations. We performed logistic regression and receiver operating curve (ROC) analyses for the different classifications with estimations of area under the curve (AUC) for comparisons. RESULTS: Mean age at baseline was 60 years (SD 11), 55% were male. Mean duration of follow-up was 91 months. By GOLD 2011, 21% were classified as group A, 29% group B, 6% group C, and 43% as group D, corresponding percentages for GOLD 2017 were: 25%, 52%, 3%, and 20%. The GOLD 2011 classification had higher AUC values than the GOLD 2017 group ABCD classification for respiratory mortality and hospitalization, but after inclusion of airflow limitation severity in GOLD 2017 groups 2A–4D, AUC values were significantly higher with GOLD 2017. CONCLUSION: In a clinically relevant sample of COPD patients, the GOLD 2017 classification doubles the prevalence of group B and halves the prevalence of groups C and D as compared to the GOLD 2011 classification. The prediction of respiratory mortality and respiratory hospitalization was better for GOLD 2017 2A–4D taking airflow limitation severity into account, as compared to GOLD 2017 ABCD and GOLD 2011.
format Online
Article
Text
id pubmed-6662162
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66621622019-08-14 Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort Le, Lan Ai Kieu Johannessen, Ane Hardie, Jon Andrew Johansen, Odd Erik Gulsvik, Amund Vikse, Bjørn Egil Bakke, Per Int J Chron Obstruct Pulmon Dis Original Research RATIONALE: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 is based on an ABCD assessment tool of symptoms and exacerbation history and grade 1–4 of airflow limitation severity, facilitating classification either into 4 groups (ABCD) or 16 groups (1A-4D). We aimed to compare the GOLD 2011, GOLD 2017 ABCD, and GOLD 2017 1A-4D classifications in terms of their distribution and prediction of mortality and hospitalizations. METHODS: In the GenKOLS study, 912 COPD patients with FEV1 less than 80% of the predicted answered questionnaires and performed lung function testing in 2003–2005. The patients were recruited from a hospital patient registry (n=662) and from the general population (n=250), followed up until 2011 with respect to all-cause and respiratory mortality, and all-cause and respiratory hospitalizations. We performed logistic regression and receiver operating curve (ROC) analyses for the different classifications with estimations of area under the curve (AUC) for comparisons. RESULTS: Mean age at baseline was 60 years (SD 11), 55% were male. Mean duration of follow-up was 91 months. By GOLD 2011, 21% were classified as group A, 29% group B, 6% group C, and 43% as group D, corresponding percentages for GOLD 2017 were: 25%, 52%, 3%, and 20%. The GOLD 2011 classification had higher AUC values than the GOLD 2017 group ABCD classification for respiratory mortality and hospitalization, but after inclusion of airflow limitation severity in GOLD 2017 groups 2A–4D, AUC values were significantly higher with GOLD 2017. CONCLUSION: In a clinically relevant sample of COPD patients, the GOLD 2017 classification doubles the prevalence of group B and halves the prevalence of groups C and D as compared to the GOLD 2011 classification. The prediction of respiratory mortality and respiratory hospitalization was better for GOLD 2017 2A–4D taking airflow limitation severity into account, as compared to GOLD 2017 ABCD and GOLD 2011. Dove 2019-07-23 /pmc/articles/PMC6662162/ /pubmed/31413559 http://dx.doi.org/10.2147/COPD.S194019 Text en © 2019 Le et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Le, Lan Ai Kieu
Johannessen, Ane
Hardie, Jon Andrew
Johansen, Odd Erik
Gulsvik, Amund
Vikse, Bjørn Egil
Bakke, Per
Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
title Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
title_full Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
title_fullStr Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
title_full_unstemmed Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
title_short Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
title_sort prevalence and prognostic ability of the gold 2017 classification compared to the gold 2011 classification in a norwegian copd cohort
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662162/
https://www.ncbi.nlm.nih.gov/pubmed/31413559
http://dx.doi.org/10.2147/COPD.S194019
work_keys_str_mv AT lelanaikieu prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort
AT johannessenane prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort
AT hardiejonandrew prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort
AT johansenodderik prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort
AT gulsvikamund prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort
AT viksebjørnegil prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort
AT bakkeper prevalenceandprognosticabilityofthegold2017classificationcomparedtothegold2011classificationinanorwegiancopdcohort